Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 3 2Phase 1 2Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1Advanced Solid Tumor 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × donafenib × Clear all
NCT04402723 2022-12-01

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1 Terminated
8 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04472858 2022-11-29

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1 Unknown
30 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡